XML 24 R11.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Balance Sheet Components | 6 Months Ended
--- | ---
Jun. 30, 2024
Balance Sheet Components |
Balance Sheet Components | 5. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, | ​ | December 31,
(in thousands) | ​ | 2024 |  | 2023
Machinery and equipment | ​ | $ | 13,136 | ​ | $ | 13,124
Computer equipment and software | ​ |  | 3,566 | ​ |  | 3,546
Furniture and fixtures | ​ |  | 1,055 | ​ |  | 1,055
Leasehold improvements | ​ |  | 5,751 | ​ |  | 5,751
Finance lease right of use assets | ​ | ​ | 145 | ​ | ​ | 2,294
Total property and equipment | ​ |  | 23,653 | ​ |  | 25,770
Accumulated depreciation and amortization | ​ |  | (20,319) | ​ |  | (20,651)
Property and equipment, net | ​ | $ | 3,334 | ​ | $ | 5,119
​ Depreciation and amortization expense related to property and equipment, net was $0.5 million and $1.1 million for the three and six months ended June 30, 2024, respectively, and $0.8 million and $1.7 million for the three and six months ended June 30, 2023, respectively. ​ As of June 30, 2024 and December 31, 2023, the net book value of software implementation costs related to hosting arrangements was $2.6 million and $3.2 million, respectively, and the amortization expense was immaterial for all periods presented. ​ Intangible Assets, Net Intangible assets, net consisted of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, | ​ | December 31,
(in thousands) | ​ | 2024 |  | 2023
Finite-lived assets, net of accumulated amortization of $1,411 and $639, as of June 30, 2024 and December 31, 2023, respectively | ​ | $ | 26,596 | ​ | $ | 41,871
Indefinite-lived assets - in-process research and development | ​ | ​ | 28,859 | ​ | ​ | 28,859
Goodwill | ​ |  | — | ​ |  | 943
Total Intangible assets, net | ​ | $ | 55,455 | ​ | $ | 71,673
​ Amortization expense related to finite-lived intangible assets was $0.7 million and $1.6 million in the three and six months ended June 30, 2024, respectively, and immaterial for the three and six months ended June 30, 2023, respectively. In connection with the CIMERLI Sale on March 1, 2024, a finite-lived asset, net of $2.1 million and goodwill of $0.9 million were derecognized. In connection with the YUSIMRY Sale on June 26, 2024, a finite-lived asset, net of $0.9 million was derecognized. ​ The exclusive license of NZV930 to Novartis Institutes, acquired as part of the Surface Acquisition, was terminated by Novartis Institutes with an effective date of October 2, 2024. As a result, the Company recognized an impairment charge of $10.6 million for the carrying value of the Novartis Institutes out-license during the three months ended March 31, 2024, which was classified within selling, general and administrative expense in the condensed consolidated statements of operations. ​ Amortization expense for the remaining finite-lived assets for each of the five succeeding fiscal years is expected to be $2.7 million. ​ Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | December 31,
(in thousands) | ​ | 2024 | ​ | 2023
Accrued commercial and research and development manufacturing | ​ | $ | 17,055 | ​ | $ | 23,470
Accrued co-development costs and milestone payments | ​ | ​ | 12,500 | ​ | ​ | 26,812
Accrued royalties | ​ | ​ | 3,583 | ​ | ​ | 42,031
Royalty Fee Derivative Liability (Note 8) | ​ | ​ | 9,202 | ​ | ​ | —
Revenue participation liability, current (Note 8) | ​ | ​ | 2,682 | ​ | ​ | —
Accrued other | ​ |  | 14,586 | ​ |  | 7,628
Lease liabilities, current | ​ | ​ | 1,436 | ​ | ​ | 2,145
Contingent consideration, current | ​ | ​ | — | ​ | ​ | 3,300
Total Accrued and other current liabilities | ​ | $ | 61,044 | ​ | $ | 105,386
​ Other Liabilities, Non-current Other liabilities, non-current consisted of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | December 31,
(in thousands) | ​ | 2024 | ​ | 2023
Contingent consideration, non-current | ​ | $ | 632 | ​ | $ | 1,172
Deferred tax liability | ​ | ​ | 1,102 | ​ | ​ | 1,102
Revenue participation liability, non-current (Note 8) | ​ | ​ | 25,963 | ​ | ​ | —
Other | ​ | ​ | — | ​ | ​ | 10,287
Total Other liabilities, non-current | ​ | $ | 27,697 | ​ | $ | 12,561
​

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration